ANAB
ANAPTYSBIO, INC
NASDAQ · Healthcare · Biotechnology · US
$49.24
+5.64%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$47.33
From 52W high−29.47%
Volume468138.00
Market cap$1.47B
P/E (TTM)7.3x
P/S (TTM)6.2x
Div yield—
Key dataOct 19, 2026
Open
$47.33
From 52W high
−29.47%
Volume
468138.00
Market cap
$1.47B
ValuationView details →
P/E (Fwd)
5.5x
EV/EBITDA
17.2x
P/E (TTM)
7.3x
RSI (14)
47.8
MomentumView details →
1D Return
+5.64%
YTD Return
+52.18%
SummaryUpdated Jun 1, 2026
AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company founded in 2005 and based in San Diego, California. The company was originally incorporated as Anaptys Biosciences, Inc. before changing its name to AnaptysBio in July 2006. AnaptysBio went public in January 2017 and focuses on developing innovative therapeutic antibody candidates for treating inflammatory diseases and immuno-oncology conditions. The company leverages its proprietary antibody discovery platform to create targeted treatments that modulate immune system responses.
Similar companies
Latest newsMore news →
AnaptysBio, Inc. reported a Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.46 loss and improving from a $1.34 loss per share a year earlier.28d agoAnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.28d ago